Cargando…
Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: Lessons from the past and novel mechanisms of action for the future
In the past, the development of more effective, safe, convenient, broadly applicable, and easy to manufacture vaccines for allergen-specific immunotherapy (AIT) has been limited by the poor quality of natural allergen extracts. Progress made in the field of molecular allergen characterization has no...
Autores principales: | Valenta, Rudolf, Campana, Raffaela, Focke-Tejkl, Margit, Niederberger, Verena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4861208/ https://www.ncbi.nlm.nih.gov/pubmed/26853127 http://dx.doi.org/10.1016/j.jaci.2015.12.1299 |
Ejemplares similares
-
Allergen Peptides, Recombinant Allergens and Hypoallergens for Allergen-Specific Immunotherapy
por: Marth, Katharina, et al.
Publicado: (2014) -
Recombinant allergy vaccines based on allergen-derived B cell epitopes
por: Valenta, Rudolf, et al.
Publicado: (2017) -
Past, present, and future of allergen immunotherapy vaccines
por: Dorofeeva, Yulia, et al.
Publicado: (2020) -
Allergen Extracts for In Vivo Diagnosis and Treatment of Allergy: Is There a Future?
por: Valenta, Rudolf, et al.
Publicado: (2018) -
The Molecular Allergen Recognition Profile in China as Basis for Allergen-Specific Immunotherapy
por: D’souza, Nishelle, et al.
Publicado: (2021)